3D in vitro modeling of the central nervous system

Abstract

There are currently more than 600 diseases characterized as affecting the central nervous system (CNS) which inflict neural damage. Unfortunately, few of these conditions have effective treatments available. Although significant efforts have been put into developing new therapeutics, drugs which were promising in the developmental phase have high attrition rates in late stage clinical trials. These failures could be circumvented if current 2D in vitro and in vivo models were improved. 3D, tissue-engineered in vitro systems can address this need and enhance clinical translation through two approaches: (1) bottom-up, and (2) top-down (developmental/regenerative) strategies to reproduce the structure and function of human tissues. Critical challenges remain including biomaterials capable of matching the mechanical properties and extracellular matrix (ECM) composition of neural tissues, compartmentalized scaffolds that support heterogeneous tissue architectures reflective of brain organization and structure, and robust functional assays for in vitro tissue validation. The unique design parameters defined by the complex physiology of the CNS for construction and validation of 3D in vitro neural systems are reviewed here.

Keywords: 3D in vitro model; Blood–brain barrier; Central nervous systems; Tissue engineering.

Figure 1

Graphical representation of 3D tissue modeling subfield. Amy Hopkins, Elise DeSimone, Karolina Chwalek and David Kaplan, Progress in Neurobiology.

Figure 2

A graphical summary of key milestones in clinical neuroscience. Amy Hopkins, Elise DeSimone, Karolina Chwalek and David Kaplan, Progress in Neurobiology.

Figure 3

Traditional tissue engineering techniques. Amy Hopkins, Elise DeSimone, Karolina Chwalek and David Kaplan, Progress in Neurobiology.

Figure 4

Representation of the PNN. Amy Hopkins, Elise DeSimone, Karolina Chwalek and David Kaplan, Progress in Neurobiology.